Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

A $10.3 million grant from the California Institute for Regenerative Medicine (CIRM), the state’s stem cell agency, will fund ...

SemiAnalysis debunks the $6 million DeepSeek AI training cost myth, revealing a massive $1.3 billion investment in ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...